The comparison results were consistent with our prior results [21], showing that tumor size on Day 49 in the STING/α-PD-1 + α-CTLA-4 group was significantly smaller than that in the STING agonist alone or the ICIs alone group (p = 0.018 and 0.032, respectively). Here, STING1 is linked to neoplasm.